Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• GenFlat to trial collapsible containers in Vietnam with Group Global One
• Western Digital (WDC) call put ratio 1 call to 1.2 puts on 57K contracts